Comprehensive Analysis of the Macular Edema and Macular Degeneration Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Projected Compound Annual Growth Rate (CAGR) of the Macular Edema and Macular Degeneration Market from 2025 to 2034, and What Factors Influence It?
The market size for macular edema and macular degeneration has seen robust growth in the past few years. The market value is predicted to rise from $9.65 billion in 2024 to $10.43 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this historical growth include an aging population, the prevalence of diabetes, early detection and awareness, worldwide eye health initiatives, advancements in pharmaceuticals, and advocacy and support for patients.
The market for macular edema and macular degeneration is projected to experience robust expansion in the forthcoming years, escalating to $13.71 billion by 2029 with a CAGR of 7.1%. This growth during the forecast period is due to various factors such as the adoption of personalized medicine strategies, increased awareness in developing markets, emphasis on combination therapies, incorporation of teleophthalmology services, and worldwide aging demographics. Key trends expected during this projection period include the progression of sustained-release drug delivery systems, the incorporation of gene therapies, the creation of innovative imaging technologies, personalized treatment strategies based on biomarkers, the use of teleophthalmology for remote monitoring, and advancements in AI for diagnostic purposes.
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the macular edema and macular degeneration Market?
The growth of the macular edema and macular degeneration market is likely to be boosted by the expanding population of people with diabetes. Diabetes, a long-term medical condition characterized by elevated blood glucose (sugar) levels, can damage eye blood vessels leading to macular edema and macular degeneration. For example, The National Health Service (NHS England), a UK-based publicly funded healthcare system reported in June 2024 that there was an 18% rise in pre-diabetes cases to 3,615,330 in 2023, up from 3,065,825 in 2022. The rise of diabetes cases among those under 40 was particularly significant, up nearly 25% from 173,166 in 2022 to 216,440 in 2023. Therefore, this increasing rate of diabetes fuels the growth of the macular edema and macular degeneration market. The growth of the macular edema and macular degeneration market is also potentially influenced by an escalating prevalence of eye disorders. A wide spectrum of disorders can affect the visual system and potentially cause macular edema due to fluid leakage in the macula. The abnormal growth and leakage of blood vessels typical of wet AMD directly cause fluid accumulation in the macula. As an illustration, a report published by National Eye Health Week in September 2023 presented that the chief cause of blindness in the UK, late-stage age-related macular degeneration (AMD), is predicted to increase by 25% by 2032. The other eye disorders, early-stage AMD (drusen) will increase by 16%, cataracts by 25%, and glaucoma by 17% by 2032. Hence, the growing frequency of eye disorders propels the growth of the macular edema and macular degeneration market.
Request Your Free Macular Edema and Macular Degeneration Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
Who Are the Leading Players Fueling Growth in the Macular Edema and Macular Degeneration Market?
Major companies operating in the macular edema and macular degeneration market report are:
• F. Hoffmann La Roche Ltd._x000D_
• AbbVie Inc._x000D_
• Bayer AG_x000D_
• Novartis AG_x000D_
• GlaxoSmithKline PLC_x000D_
What Are the Emerging Trends Shaping the Future of the Macular Edema and Macular Degeneration Market?
Primary entities functioning in the macular edema and macular degeneration market are centering their efforts on the development of outstanding products like Vabysmo (faricimab-svoa) to escalate their market gains. Vabysmo (faricimab-svoa) is a therapeutic drug implemented for the alleviation of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For example, Genentech Inc., a biotechnological company from the USA, received the approval for Vabysmo (faricimab-svoa) from the Food and Drug Administration earlier in January 2022. This medication is a bispecific antibody that aims at the vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), thus becoming the premier bispecific monoclonal antibody for both such illnesses. Faricimab holds great promise of transforming into a blockbuster treatment for nAMD and DME. The approval of it from FDA and EU marks a significant achievement for Genentech and Roche.
Pre-order Your Report for Quick and Easy Delivery!
What Are the Key Components of the Macular Edema and Macular Degeneration Market, and How Do Its Segments Perform?
The macular edema and macular degeneration market covered in this report is segmented –
1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy
Which Regions Are Driving Growth in the Macular Edema and Macular Degeneration Market?
North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Defines the Scope of the Macular Edema and Macular Degeneration Market?
Macular edema and macular degeneration are two different eye conditions that can affect vision. Macular edema is swelling in the part of the retina at the back of the eye, which can cause blurry vision. Macular degeneration is a condition that affects the macula, a part of the retina at the back of the eye that is responsible for central vision. They can be caused by many different conditions, including diabetic retinopathy, retinal vein occlusion, and inflammation, and include age, genetics, smoking, high blood pressure, and obesity.
Browse Through More Similar Reports By The Business Research Company:
Hyperlipidemia Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024
Macular Degeneration Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
